The approval by the National Health Surveillance Agency (Anvisa) of the registration of the first national semaglutide, at the end of May, which will be produced by EMS , has intensified the battle for lower prices of slimming pens in the Brazilian market.
Now, the market leader, the American company Eli Lilly, owner of Mounjaro, a pen analog of GLP-1 based on tirzepatide, considered more efficient than semaglutide, has decided to enter the fray.
Starting this Friday, June 12th, the company began offering a discount program for purchasing "combos," with reductions of up to 35%. The new prices will be available both in pharmacies and online.
The package containing one box of the 2.5 mg pen and one of the 5 mg pen, which previously cost R$ 3,400, will now cost R$ 2,250, a reduction of over R$ 1,100.
In the plan with a dosage of 10 mg, the kit with two boxes will cost R$ 4,600, a discount of R$ 2,600 from the original price of the same quantity.
Last month, Mounjaro became the world's best-selling drug, surpassing Merck's cancer drug Keytruda, with global revenue of US$8.7 billion in the first quarter of 2026.
Although it is the most sought-after slimming pen in the pharmaceutical retail market, its high cost has been cited as a barrier to entry for customers with slightly lower purchasing power, who have been opting for more affordable options.
Eli Lilly's initiative comes just days before Ozivy, the semaglutide manufactured by EMS, arrives in drugstores. The new pen from the company led by the Sanchez family will be on the market starting Monday, June 15th.
The company also announced a benefits plan for those who join the discount program and register on the company's website. The product will cost R$ 452, in a box containing one pen.
For a three-month treatment, the cost will be R$ 863.23, with two boxes of 1mg each. The monthly cost, in this case, is R$ 287. From the fourth month onwards, it will cost R$ 498.
In April, NeoFeed reported that Eurofarma would become responsible for marketing the Poviztra and Extensior pens, produced by the Danish company Novo Nordisk – which also owns Ozempic and Wegovy.
The idea was precisely to have a cheaper product line than Ozempic, but with the guarantee of being manufactured by the same company. Eurofarma's discount plan is R$ 599 for two boxes of Poviztra, one of 0.25 mg and the other of 0.5 mg. Therefore, each box costs R$ 299.50.
Novo Nordisk itself reduced the price of the pen as soon as Eli Lilly entered the national market in June of last year. Today, the Ozempic sells for less than R$ 1,000.
Now, the trend is that this competition for patients will become even stronger with the arrival of new players. Anvisa is analyzing 17 registration requests for slimming pens in Brazil.
NeoFeed revealed that the next in line is Ávita Care , which has been working to get its approval in June. The company represents the European pharmaceutical company Adalvo, from Malta, in Brazil, which will produce the pen in factories in China and Canada.
Ávita's plan is to transfer the marketing of the pen to the Swiss company Sandoz, headed in Brazil by Isabella Wanderley, who was previously CEO of Novo Nordisk in the country, following the same model as Eurofarma and Novo Nordisk.
The market for slimming pens in Brazil is expected to reach R$ 15.6 billion by 2026, 50% higher than the R$ 10 billion recorded last year.
Contacted by NeoFeed , Eli Lilly confirmed the discount package and stated that the information is already available on the Lilly Better For You program platform.
